Study of a new drug combined with standard therapy for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a new medicine (IPN60340) to the usual two-drug combo (azacitidine and venetoclax) helps people with newly diagnosed acute myeloid leukemia (AML) who are not able to receive intensive chemotherapy. It may offer a more effective treatment option for those who cannot tolerate stronger chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with acute myeloid leukemia (AML) recently, and it has not been treated before
- You are not eligible for intensive chemotherapy because of your age or other health problems
- Your overall health status is generally okay (you are able to do light activities or are up and about more than half the day)
- You do not have certain types of AML (like acute promyelocytic leukemia) or other specific conditions
- You are not currently taking certain medications that could interfere with the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
This trial tests a new drug (CLN-049) combined with two standard AML medicines (azacitidine and venetoclax) for people who are newly diagnosed with AML and cannot have intensive chemotherapy. It aims to see if this combination is safe and effective for those who are not fit for the usual strong treatment.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.